Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy

Grössmann N, Wolf S
Record ID 32017000166
English
Authors' recommendations: Currently, no cost estimates are available for neratinib neither in the US nor in Europe. However, additional costs for possible prospective biomarkers as well as increased costs due to the treatment and monitoring of possible gastrointestinal and cardiac toxicities are likely to incur. Although neratinib offers an improvement in invasive DFS, the gastrointestinal toxicities in combination with possible cardiac toxicities suggest an unfavourable benefit-risk ratio. Further studies are needed to determine the appropriate patient population, to verify the long-term benefit, and to exclude toxic effects of the cardiovascular system.
Details
Project Status: Completed
Year Published: 2017
URL for additional information: http://eprints.hta.lbg.ac.at/1116
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Breast Neoplasms
  • Combined Modality Therapy
  • Humans
  • Quinolines
  • Trastuzumab
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.